Results 31 to 40 of about 103,351 (342)

Botulinum toxin type A in treatment of chronic migraine, spasticity and bruxism

Journal of Education, Health and Sport, 2023
Introduction: Nowadays, botulinum toxin has found use in many disease entities such as chronic migraine, spasticity, bruxism and many others. Among serotypes A-E, type A is mainly used in treatment.
Klaudia Kuliga, Katarzyna Dobko, Gabriela Frącz, Agata Glac, Kinga Musz, Natalia Sejnowska, Agnieszka Socha, Agata Surowiec, Kinga Śnieżek, Anna Zając   +9 more
doaj   +1 more source

Cost minimization analysis of BoNT-As in the treatment of upper limb spasticity and cervical dystonia [PDF]

, 2016
Botulinum toxin type A (BoNT-A) injections are recommended for the management of upper limb spasticity (ULS) and cervical dystonia (CD). The main aim of this cost minimization analysis (CMA) was to compare the annual cost per patient for three BoNT-As ...
Bartolomei, Luigi, Bentivoglio, Anna Rita, Bizzarini, Massimo, Caglioni, Patrizia Maria, Cerbarano, Luana, Frontoni, Marco, Lus, Giacomo, Majorana, Giovanni, Nassetti, Stefania Alessandra, Osio, Maurizio, Ravasio, Roberto, Ravenni, Roberta, Santoro, Antonio, Smania, Nicola, Torlizzi, Flavia, Valvo, Sebastiana Claudia   +15 more
core   +1 more source

Safety and patient satisfaction of abobotulinumtoxinA for aesthetic use. A systematic review [PDF]

, 2017
A systematic review of the published literature (from January 2000 to January 2016) to ascertain the safety of, and patient satisfaction with, the aesthetic use of abobotulinumtoxinA was conducted.
Cohen, Joel L, Scuderi, Nicolo'
core   +1 more source

Development of a technique for DNA detection and identification of toxigenic strains of Clostridium botulinum types A, B, E by the Real-Time PCR method

Вестник войск РХБ защиты, 2023
Botulism is dangerous toxic infection caused by a toxin produced by the bacterium Clostridium botulinum. The mortality rate from botulism can reach 70% of all cases of illness in case of untimely initiation of treatment.
D. S. Yanov, A. V. Kuznetsovskiy, M. I. Dubrovin, A. V. Mironin, N. V. Onuchina, A. V. Filippov   +5 more
doaj   +1 more source

Arrangement of the Clostridium baratii F7 toxin gene cluster with identification of a σ factor that recognizes the botulinum toxin gene cluster promoters.

PLoS ONE, 2014
Botulinum neurotoxin (BoNT) is the most poisonous substances known and its eight toxin types (A to H) are distinguished by the inability of polyclonal antibodies that neutralize one toxin type to neutralize any of the other seven toxin types.
Nir Dover, Jason R Barash, Julianne N Burke, Karen K Hill, John C Detter, Stephen S Arnon   +5 more
doaj   +1 more source

Safety and efficacy of a propofol and ketamine based procedural sedation protocol in children with cerebral palsy undergoing botulinum toxin A injections. [PDF]

, 2019
Background Pediatric patients with cerebral palsy (CP) often undergo intramuscular botulinum toxin (BoNT‐A) injections. These injections can be painful and may require procedural sedation.
Abu-Sultaneh, Samer, Abulebda, Kamal, Louer, Ryan, Lutfi, Riad, McKinney, Renee C.   +4 more
core   +1 more source

Tetanus: Pathophysiology, Treatment, and the Possibility of Using Botulinum Toxin against Tetanus-Induced Rigidity and Spasms

Toxins, 2013
Tetanus toxin, the product of Clostridium tetani, is the cause of tetanus symptoms. Tetanus toxin is taken up into terminals of lower motor neurons and transported axonally to the spinal cord and/or brainstem. Here the toxin moves trans-synaptically into
Bjørnar Hassel
doaj   +1 more source

Service-based survey of dystonia in Munich [PDF]

, 2002
We performed a service-based epidemiological study of dystonia in Munich, Germany. Due to favourable referral and treatment patterns in the Munich area, we could provide confident data from dystonia patients seeking botulinum toxin treatment.
Ben-Shlomo, Y., Ceballos-Baumann, Andres, Conrad, B., Gasser, T., Kamm, C., Konkiewitz, E. C., Trender-Gerhard, I., Warner, T.   +7 more
core   +1 more source

Botulinum Toxin for Pain [PDF]

Drugs in R & D, 2008
Botulinum toxin (BTX) injection is being increasingly used 'off label' in the management of chronic pain. Data support the hypothesis of a direct analgesic effect of BTX, different to that exerted on muscle. Although the pain-reducing effect of BTX is mainly due to its ability to block acetylcholine release at the synapse, other effects on the nervous ...
Valeria Tugnoli, Roberto Casale
openaire   +3 more sources

Botulinum toxin A for the Treatment of Overactive Bladder

Toxins, 2016
The standard treatment for overactive bladder starts with patient education and behavior therapies, followed by antimuscarinic agents. For patients with urgency urinary incontinence refractory to antimuscarinic therapy, currently both American Urological
Po-Fan Hsieh, Hung-Chieh Chiu, Kuan-Chieh Chen, Chao-Hsiang Chang, Eric Chieh-Lung Chou   +4 more
doaj   +1 more source